(to be used for	ANSMITTAL FORM all correspondence after initial file (Pages in This Submission	Filing Date First Named Inventor Art Unit Examiner Name Attorney Docket Number	January 7 Corvalan of 1644 Phuong N Cura 961	r, 2002 et al. I. Huynh	
Amendme And Ai Extension Express A Information Certified Courner Reply to Incomplete Recomplete	fiter Final ffidavits/declaration(s) n of Time Request Abandonment Request on Disclosure Statement Copy of Priority tt(s) Missing Parts/ te Application eply to Missing Parts nder 37 CFR 1.52 or 1.53	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocatio Change of Correspondence A Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on CD Remarks URE OF APPLICANT, ATTO	n Address	After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): Return Postcard Exhibits A, B, and C	
Firm Name Signature	CuraGen Corporation Signature				
Printed name Date	Wendy L. Davis May 2, 2005	I	Reg. No.	38, 427	
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature					

Lissette Cartagena-Perez Typed or printed name

May 2, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

O Date of Deposit: May 2, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TITLICANIS.

Corvalan et al.

SERIAL NUMBER:

10/041,860

EXAMINER:

Phuong N Huynh

FILING DATE:

January 7, 2002

ART UNIT:

1644

For:

ANTIBODIES DIRECTEDTO PDGFD AND USES THEREOF.

Commissioner for Patents P.O. Box 1450

Washington, D.C. 22313-1450

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.116.

This paper is in response to the March 1, 2005 Final Office Action in connection with the above-referenced application. Please enter the following amendments and consider the remarks below. Included with this response are: Exhibit A, Ostendorf, T. et al "A Fully Human Monoclonal Antibody (CR002) Identifies PDGF-D as a Novel Mediator of Mesangioproliferative Glomerulonephritis", J Am Soc Nephrol 14:2237-2247, 2003; Exhibit B, Rabbitts, T. H. (1983). Biochem. Soc. Trans., 11, 119-126; and Exhibit C, Corbett et al (1997). J. Mol. Biol., 270, 587-597. The Commissioner is hereby authorized to charge any fees that may be due, or credit any overpayment of same to Deposit Account No. 502648, Reference No. Cura 961.

Amendments to the Claims are reflected in the listing of the claims which begins on page 2 of this paper.

Amendments to the Drawings begins on page 6 of this paper.

Remarks begin on page 7 of this paper.